The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01A | Antiinfectives | |
| 4 | S01AE | Fluoroquinolones | |
| 5 | S01AE07 |
| Active Ingredient | Description | |
|---|---|---|
| Moxifloxacin |
Moxifloxacin, a fourth-generation fluoroquinolone, has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens. The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MOXIVIG Eye drops | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
